Bath & Bodyworks Inc. (NYSE: BBWI): This year will be a tough one for its Bear of the Day stock, says Zacks. Shares of the personal care company have traded as high as $58.17 in the past year but closed most recently at $35.36. That is down about 16% year to date.
Camden Property Trust (NYSE: CPT): Goldman Sachs lowered its $134 target price on the Neutral-rated stock to $120. The consensus target is $133.10. The stock closed on Tuesday at $105.95.
CION Investment Corp. (NASDAQ: CION): Wells Fargo’s downgrade to Equal Weight from Overweight included a target price cut from $10.50 to $9.25, the same as the consensus target. The stock closed on Tuesday at $128.73.
Core Laboratories N.V. (NYSE: CLB): BofA Securities downgraded the stock from Neutral to Underperform with a $21.50 target price. The consensus target is $23.19. The stock closed on Tuesday at $22.00.
Danaher Corp. (NYSE: DHR): When Wells Fargo boosted its Equal Weight rating to Overweight, its target price rose to $285 from $275. The consensus target is up at $300.30, and shares closed on Tuesday at $256.14.
Enterprise Products Partners L.P. (NYSE: EPD): The $29 target price at Barclays is now $30, and the firm’s Overweight rating remains. The consensus target is $31.80. The shares closed on Tuesday at $27.01.
Humana Inc. (NYSE: HUM): Jefferies reiterated a Buy rating with a $612 target price. The consensus target is $602.76. Tuesday’s close was at $512.68.
Lear Corp. (NYSE: LEA): BofA Securities hiked its $165 target price to $170 and kept its Buy rating. The consensus target is $162.64. The stock closed at $136.75 on Tuesday.
Lovesac Co. (NASDAQ: LOVE): Oppenheimer reiterated an Outperform rating. Its $60 target price compares with a $52.50 consensus target and Tuesday’s close at $29.87, which was up almost 4% on the day after positive analyst commentary.
Marathon Petroleum Corp. (NYSE: MPC): Wells Fargo’s downgrade to Equal Weight from Overweight came with a target price cut from $153 to $135. The consensus target is $153.00. The stock closed on Tuesday at $129.06.
Merus N.V. (NASDAQ: MRUS): Stifel raised its $34 target price to $44 while keeping a Buy rating. The consensus target is $40.60. Tuesday’s $20.45 close came after a 14% plunge in the wake of clinical data.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
